Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 291-295

  Baldi, Licia ^a   Mengoli, Maria Cecilia ^b   Bisagni, Alessandra ^a   Banzi, Maria Chiara ^a   Boni, Corrado ^a   Rossi, Giulio ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adenocarcinoma; ALK; EGFR; FISH; Immunohistochemistry; Lung; NSCLC

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; PLACEBO; TUMOR MARKER; PROTEIN TYROSINE KINASE;

AGED; ARTICLE; BRONCHUS BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXON; FOLLOW UP; GENE REARRANGEMENT; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG LESION; LUNG NODULE; LYMPHADENOPATHY; MALE; MISSENSE MUTATION; NON SMALL CELL LUNG CANCER; SKIN TOXICITY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR GROWTH; VISUAL DISORDER; ADENOCARCINOMA; CELL TRANSFORMATION; GENETICS; LUNG NEOPLASMS; MUTATION; NUCLEOTIDE SEQUENCE;

ADENOCARCINOMA; AGED; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84908398446     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.09.011     Document Type: Article

References (21)

1. Gainor J.F., Varghese A.M., Ou S.H.I., Kabraji S., Awad M.M., Katayama R., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin Cancer Res 2013, 19(15):4273-4281.
2. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
3. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71(18):6051-6060.
4. Kuo Y.W., WU S.G., Ho C.C., Shih J.Y. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010, 5(12):2039-2040.
5. Tiseo M., Gelsomino F., Boggiani D., Bortesi B., Bartolotti M., Bozzetti C., et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71(2):241-243.
6. Popat S., Vieira de Araujo A., Min T., Swansbury J., Dainton M., Wotherspoon A., et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011, 6(11):1962-1963.
7. Rossing H.H., Grauslund M., Urbanska E.M. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kristen sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Res Notes 2013, 6(Nov):489-497.
8. Zhang X., Zhang S., Yang X., Yang J., Zhou Q., Yin L., et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010, 9(July):188.
9. Tanaka H., Hayashi A., Morimoto T., Taima K., Tanaka Y., Shimada M., et al. A case of lung cancer adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer 2012, 12(Nov (26)):558.
10. Miyanaga A., Shimizu K., Noro R., Seike M., Kitamura K., Kosaihira S., et al. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer 2013, 13(May):262.
11. Santelmo C., Ravaioli A., Barzotti E., Papi M., Poggi B., Drudi F., et al. Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Lung Cancer 2013, 81(2):294-296.
12. Chen X., Zhang J., Hu Q., Li X., Zhou C. A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. Lung Cancer 2013, 81(2):308-310.
13. Yang J.J., Zhang X.C., Su J., Xu C.R., Zhou Q., Tian H.X., et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 2014, 20(5):1383-1392.
14. Jurgens J., Engel-Riedl W., Prickartz A., Ludwig C., Schildgen O., Tillmann R.L., et al. Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients. Future Oncol 2014, 10(4):529-532.
15. Cabillic F., Gros A., Dugay F., Begueret H., Mesturoux L., Chiforeanu D.C., Parallel F.I.S.H., et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014, 9(3):295-306.
16. Wang J., Dong Y., Cai Y., Zhou L., Wu S., Liu G., et al. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. J Cancer Res Clin Oncol 2014, 140(3):453-460.
17. Kim T.J., Park C.K., Yeo C.D., Park K., Rhee C.K., Kim J., et al. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. J Surg Oncol 2014, 10.1002/jso.23646 [Epub ahead of print].
18. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14(13):4275-4283.
19. Chiari R., Duranti S., Ludovini V., Bellezza G., Pireddu A., Minotti V., et al. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal Grosth factor receptor mutation and EML4-ALK fusion gene. J Clin Oncol 2014, 32(9):e30-e32.
20. Lovly C.M., Shaw A.T. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res 2014, 20(9):2249-2256.
21. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013, 137(6):828-860.